The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.

By K. Resnick, H. Alder, J. Hagan, D. Richardson, Carlo Maria Croce, D. Cohn. Gynecologic Oncology, 2009

676 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f7425986d8112efaf5e97ab8987615c1c70a0b06

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Ke Zen
2. Jin Wang
3. S. Sen
4. Jinyun Chen

In Molecular Biology

1. Jin Wang
2. S. Sen
3. T. Beissbarth
4. Jinyun Chen
5. Thomas Breslin
6. Michael Freeling

Citations in the corpus

• Circulating microRNAs are new and sensitive biomarkers of myocardial infarction (2010, background): “The diminution of circulating miRNAs has been reported less frequently, in liver damage,(15) acute leukaemia,(22) and ovarian cancer.(23) Which mechanisms determine the level of circulating miRNAs under physiological conditions and in response to pathological stimuli remains to be elucidated and sev”
• Circulating miRNAs are correlated with tumor progression in prostate cancer (2011, background): “epithelial carcinomas as yet.(10,12) Since miRNA profiles in tumor cells have already been shown to have a prognostic relevance for some cancer patients,(13,14) it is conceivable that”
• MicroRNAs in body fluids—the mix of hormones and biomarkers (2011, neutral): “In a study of epithelial ovarian cancer, eight serum miRNAs, among them miR-21 , miR-92 , miR-93 , miR-126 , and miR-29a , were significantly overexpressed in a set of 19 samples collected before therapy compared with 11 healthy controls”
• microRNA as Biomarkers and Diagnostics (2016, background): “…a tumor suppressor in lung cancer (Fabbri et al., 2007), hepatocellular carcinoma (Xiong et al., 2010)], and leukemia (Pekarsky and Croce, 2010) but is significantly elevated in the plasma of patients with advanced colorectal neoplasia (Huang et al., 2010) and ovarian cancer (Resnick et al., 2009).”
• Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer (2010, background): “In addition, the up-regulation of miR-92a was also observed in the serum of ovarian cancer patients.(20) Interestingly, contrary result was also reported in leukemia.”
• Secreted monocytic miR-150 enhances targeted endothelial cell migration. (2010, background): “, 2008), a large number of studies have also reported that circulating miRNAs can serve as biomarkers for various diseases (Resnick et al., 2009; Ng et al., 2009; Wang et al., 2009).”
• Circulating microRNAs in plasma of patients with gastric cancers (2010, background): “In fact, accumulating reports also suggest the potential of miRNAs in the early detection of patients with several malignancies, such as lymphoma, colorectal cancer, tongue cancer and ovarian cancer (Lawrie et al, 2008; Wong et al, 2008; Ng et al, 2009; Resnick et al, 2009).”